Surface Engineered Iron Oxide Nanoparticles Generated by Inert Gas Condensation for Biomedical Applications.

Despite the lifesaving medical discoveries of the last century, there is still an urgent need to improve the curative rate and reduce mortality in many fatal diseases such as cancer. One of the main requirements is to find new ways to deliver therapeutics/drugs more efficiently and only to affected tissues/organs. An exciting new technology is nanomaterials which are being widely investigated as potential nanocarriers to achieve localized drug delivery that would improve therapy and reduce adverse drug side effects. Among all the nanocarriers, iron oxide nanoparticles (IONPs) are one of the most promising as, thanks to their paramagnetic/superparamagnetic properties, they can be easily modified with chemical and biological functions and can be visualized inside the body by magnetic resonance imaging (MRI), while delivering the targeted therapy. Therefore, iron oxide nanoparticles were produced here with a novel method and their properties for potential applications in both diagnostics and therapeutics were investigated. The novel method involves production of free standing IONPs by inert gas condensation via the Mantis NanoGen Trio physical vapor deposition system. The IONPs were first sputtered and deposited on plasma cleaned, polyethylene glycol (PEG) coated silicon wafers. Surface modification of the cleaned wafer with PEG enabled deposition of free-standing IONPs, as once produced, the soft-landed IONPs were suspended by dissolution of the PEG layer in water. Transmission electron microscopic (TEM) characterization revealed free standing, iron oxide nanoparticles with size < 20 nm within a polymer matrix. The nanoparticles were analyzed also by Atomic Force Microscope (AFM), Dynamic Light Scattering (DLS) and NanoSight Nanoparticle Tacking Analysis (NTA). Therefore, our work confirms that inert gas condensation by the Mantis NanoGen Trio physical vapor deposition sputtering at room temperature can be successfully used as a scalable, reproducible process to prepare free-standing IONPs. The PEG- IONPs produced in this work do not require further purification and thanks to their tunable narrow size distribution have potential to be a powerful tool for biomedical applications.

An immunosensor for parasite lactate dehydrogenase detection as a malaria biomarker - Comparison with commercial test kit.

This paper describes the development of an affinity sensor for the detection of Plasmodium falciparum parasite lactate dehydrogenase (pLDH) as one of the biomarkers used for malaria detection. The gold sensor was functionalised with anti-pLDH after cleaning the electrode surface to remove impurities (120 °C, 1 h). The sensor was then treated to block unreacted groups on the surface and minimise matrix interference, before applying it in a sandwich assay to detect pLDH in buffer samples using a dose concentration assay. The sensor was optimised to achieve the best detection sensitivity before using it for pLDH detection in serum samples. The developed sensor achieved a limit of detection (LOD) of 1.80 ng mL-1 and 0.70 ng mL-1 for the detection of pLDH in buffer and in serum samples respectively. The sensor sensitivity was enhanced further with the use of AuNP conjugated to the detection anti-pLDH-enzyme, achieving an LOD of 19 pg mL-1 in buffer and 23 pg mL-1 in serum samples. The performance of the sensor was compared to commercially available Plasmodium immunochromatographic (ICT) malaria kits. The developed sensor was able to detect pLDH in the Dd2luc culture medium supernatant at 0.002% parasitaemia without the use of AuNP signal enhancement when compared to the OptiMAL-IT ICT kit (detect pLDH) and the BinaxNOW ICT kit (detection of both pLDH and PfHRP 2) samples. Therefore, the sensor developed in this work is highly sensitive and can be used for pLDH detection for on-site diagnosis of malaria. A cheap and simple device as developed in this work is required to tackle malaria detection.

Development of an Immunosensor for PfHRP 2 as a Biomarker for Malaria Detection.

Plasmodium falciparum histidine-rich protein 2 (PfHRP 2) was selected in this work as the biomarker for the detection and diagnosis of malaria. An enzyme-linked immunosorbent assay (ELISA) was first developed to evaluate the immunoreagent's suitability for the sensor's development. A gold-based sensor with an integrated counter and an Ag/AgCl reference electrode was first selected and characterised and then used to develop the immunosensor for PfHRP 2, which enables a low cost, easy to use, and sensitive biosensor for malaria diagnosis. The sensor was applied to immobilise the anti-PfHRP 2 monoclonal antibody as the capture receptor. A sandwich ELISA assay format was constructed using horseradish peroxidase (HRP) as the enzyme label, and the electrochemical signal was generated using a 3, 3', 5, 5'tetramethyl-benzidine dihydrochloride (TMB)/H2O2 system. The performance of the assay and the sensor were optimised and characterised, achieving a PfHRP 2 limit of detection (LOD) of 2.14 ng·mL-1 in buffer samples and 2.95 ng∙mL-1 in 100% spiked serum samples. The assay signal was then amplified using gold nanoparticles conjugated detection antibody-enzyme and a detection limit of 36 pg∙mL-1 was achieved in buffer samples and 40 pg∙mL-1 in serum samples. This sensor format is ideal for malaria detection and on-site analysis as a point-of-care device (POC) in resource-limited settings where the implementation of malaria diagnostics is essential in control and elimination efforts.